Pendal Group Ltd grew its stake in shares of Syneos Health Inc (NASDAQ:SYNH) by 5.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,461 shares of the company’s stock after purchasing an additional 2,207 shares during the quarter. Pendal Group Ltd’s holdings in Syneos Health were worth $2,169,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new stake in shares of Syneos Health during the second quarter valued at $1,302,000. Aperio Group LLC boosted its position in shares of Syneos Health by 31.9% during the second quarter. Aperio Group LLC now owns 10,384 shares of the company’s stock valued at $531,000 after buying an additional 2,511 shares during the last quarter. Boston Advisors LLC purchased a new stake in shares of Syneos Health during the second quarter valued at $1,257,000. Mesirow Financial Investment Management Equity Management boosted its position in shares of Syneos Health by 26,632.0% during the second quarter. Mesirow Financial Investment Management Equity Management now owns 129,650 shares of the company’s stock valued at $6,624,000 after buying an additional 129,165 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Syneos Health during the second quarter valued at $5,423,000.
NASDAQ:SYNH traded up $0.37 on Thursday, hitting $50.14. The stock had a trading volume of 1,082 shares, compared to its average volume of 452,711. The stock has a market cap of $5.18 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 1.75 and a beta of 1.53. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99. The business has a 50-day moving average price of $49.75. Syneos Health Inc has a 52-week low of $36.26 and a 52-week high of $56.34.
Several equities research analysts recently commented on the company. Zacks Investment Research raised Syneos Health from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Barclays reissued a “hold” rating and issued a $48.00 target price on shares of Syneos Health in a research report on Wednesday, April 17th. KeyCorp raised their target price on Syneos Health from $59.00 to $63.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Finally, SunTrust Banks raised their target price on Syneos Health to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $55.75.
Syneos Health Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Story: Day Trading
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.